This inventor holds 3 USPTO granted patents. Top assignees: Pfizer Corporation, Other. Active years: 1979-1994.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Uncasville, CT (US) (1979 - 1994)
- Glastonbury, CT (US) (1994)
Company Filing History:

Years Active: 1979-1994
Title: The Innovative Contributions of Sabeto A DiRoma
Introduction
Sabeto A DiRoma is a notable inventor based in Glastonbury, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with therapeutic applications. With a total of 3 patents to his name, DiRoma's work has had a meaningful impact on drug formulation and stability.
Latest Patents
One of his latest patents involves a process for preparing aryl piperazinyl-heterocyclic compounds. This process includes reacting a piperazine salt with an alkyl halide containing compound in water, utilizing a reagent to neutralize hydrohalic acid, and heating the mixture to facilitate the coupling of the compounds. Another significant patent pertains to the monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indole-2-one hydrochloride, which demonstrates advantageous stability for formulation as a neuroleptic agent.
Career Highlights
Throughout his career, DiRoma has worked with prominent companies, including Pfizer Corporation. His experience in the pharmaceutical industry has equipped him with the knowledge and skills necessary to innovate in drug development.
Collaborations
DiRoma has collaborated with notable professionals in his field, including Frank R Busch and Dennis Michael Godek. These collaborations have likely contributed to the success of his inventions and patents.
Conclusion
Sabeto A DiRoma's contributions to the pharmaceutical industry through his innovative patents highlight his expertise and dedication to advancing drug formulation. His work continues to influence the development of effective therapeutic agents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile